Chronic Hepatitis B Market--The US to Have the Lion's Share Among the 7MM, Predicts DelveInsight
The chronic hepatitis B market size is predicted to surge owing to the increasing prevalence of the disease globally and rising awareness about early diagnosis and treatment. Advances in antiviral therapies and the development of novel treatment options are fueling market expansion.
LAS VEGAS, June 17, 2025 /PRNewswire/ -- Hepatitis B is the most widespread serious liver infection globally, caused by the hepatitis B virus (HBV), which targets and damages the liver. Millions of individuals worldwide are affected by chronic hepatitis B. The virus spreads through contact with infected blood and bodily fluids, including transmission via unprotected sex, sharing of contaminated needles, use of illegal drugs, and exposure to unsterilized medical equipment.
In most cases, hepatitis B resolves on its own within 1 to 2 months. However, if the infection persists beyond six months, it can become chronic, potentially leading to ongoing liver inflammation, cirrhosis (liver scarring), liver cancer, or liver failure. As of 2024, around 5 million people across the 7MM were living with chronic hepatitis B. Among these, 85% had compensated liver function, while the remaining 15% had progressed to decompensated liver disease.
Currently, there is no definitive cure for hepatitis B. Antiviral medications and interferon injections can help manage the disease by reducing viral activity and easing symptoms, but they do not eliminate the virus entirely. If the infection persists beyond six months, it is classified as chronic, making patients eligible for drug therapy, particularly those with active liver disease.
Learn more about the chronic hepatitis B virus market @ New Treatment for Chronic Hepatitis B
The US FDA has approved seven medications for treatment: two injectable interferons and five oral antiviral drugs. These treatments must be taken daily and work by suppressing viral replication, thereby reducing liver inflammation and potential damage.
VEMLIDY (tenofovir alafenamide), developed by Gilead Sciences, is an innovative, targeted prodrug of tenofovir formulated as an oral tablet. In March 2024, Gilead announced that the FDA had approved a supplemental New Drug Application (sNDA) for VEMLIDY 25 mg, allowing its once-daily use in pediatric patients aged 6 years and older and weighing at least 25 kg who have chronic hepatitis B (CHB) infection with compensated liver disease.
Earlier, in November 2022, the FDA approved the same 25 mg dose for once-daily use in children aged 12 and above with CHB and compensated liver disease. The initial FDA approval came in November 2016 for adult patients with CHB and compensated liver function.
In January 2017, Gilead announced that the European Commission (EC) had granted marketing authorization for VEMLIDY 25 mg to treat CHB in adults and adolescents aged 12 and older who weigh at least 35 kg.
Additionally, in December 2016, Japan's Ministry of Health, Labour and Welfare (MHLW) approved VEMLIDY for the treatment of chronic hepatitis B in patients showing active viral replication and abnormal liver function.
Find out more on FDA-approved chronic hepatitis B drugs @ Chronic Hepatitis B (CHB) Market
The chronic hepatitis B treatment drug market is continuously evolving. Several pharma companies are evaluating their lead assets in different phases of development. Many potential therapies are being investigated to manage chronic hepatitis B.
Some of the drugs in the pipeline include Imdusiran (AB-729) (Arbutus Biopharma), GSK3228836 (bepirovirsen) (GlaxoSmithKline), Tobevibart (VIR-3434) + elebsiran (VIR-2218) ± PEG-IFN-a (Vir Biotechnology), and others.
Even though it is too soon to comment on the above-mentioned promising candidate to enter the market during the forecast period (2025–2034), it is safe to assume that the future of this market is bright.
Discover which therapies are expected to grab major chronic hepatitis B treatment drug market @ Chronic Hepatitis B Market Report
Daplusiran (also known as tomligisiran, formerly JNJ-3989/GSK5637608) is an experimental siRNA-based therapy targeting hepatitis B virus (HBV). It is being studied in combination with bepirovirsen in a sequential regimen for adult patients with chronic hepatitis B who are non-cirrhotic and receiving nucleos(t)ide analogue (NA) therapy.
In October 2023, GSK and Arrowhead Pharmaceuticals announced an agreement with Janssen Pharmaceuticals to acquire the exclusive global rights to further develop and commercialize JNJ-3989. Janssen had originally licensed the drug (then called ARO-HBV) from Arrowhead in 2018.
Imdusiran is an RNA interference (RNAi) therapy designed to suppress all HBV viral proteins and antigens, including HBsAg, which is believed to be critical for restoring the immune system's ability to fight the virus. It uses Arbutus' proprietary GalNAc-conjugated delivery platform to specifically target liver cells (hepatocytes), allowing for subcutaneous administration.
Arbutus plans to launch a Phase IIb clinical trial in the first half of 2025 to evaluate imdusiran in combination with interferon (IFN) and NA therapy.
Discover more about drugs for chronic hepatitis B in development @ Chronic Hepatitis B Clinical Trials
The anticipated launch of these emerging therapies for chronic hepatitis B are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the chronic hepatitis B market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
DelveInsight estimates that the market size for chronic hepatitis B is expected to grow at a significant CAGR by 2034. In 2024, the United States dominated the CHB market among the 7MM, capturing approximately 72% of the total market share. The market size of chronic hepatitis B is expected to grow due to several factors, including rising global prevalence of hepatitis B virus infection and increasing awareness about the disease. Advances in antiviral therapies and growing screening initiatives also boost market growth by enabling early diagnosis and improved disease management.
DelveInsight's latest published market report, titled as Chronic Hepatitis B Market Insight, Epidemiology, and Market Forecast – 2034, will help you to discover which market leader is going to capture the largest market share. The report provides comprehensive insights into the chronic hepatitis B country-specific treatment guidelines, patient pool analysis, and epidemiology forecast to help understand the key opportunities and assess the market's underlying potential. The chronic hepatitis B market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalent Cases of Chronic Hepatitis B
Total Diagnosed Cases of Chronic Hepatitis B
Chronic Hepatitis B Cases by Age Group
Chronic Hepatitis B Cases by Gender
Treated Cases of Chronic Hepatitis B
Chronic Hepatitis B Cases by Impact on Liver
The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM chronic hepatitis B market. Highlights include:
10-year Forecast
7MM Analysis
Epidemiology-based Market Forecasting
Historical and Forecasted Market Analysis upto 2034
Emerging Drug Market Uptake
Peak Sales Analysis
Key Cross Competition Analysis
Industry Expert's Opinion
Access and Reimbursement
Download this chronic hepatitis B market report to assess the epidemiology forecasts, understand the patient journeys, know KOLs' opinions about the upcoming treatment paradigms, and determine the factors contributing to the shift in the chronic hepatitis B market. Also, stay abreast of the mitigating factors to improve your market position in the chronic hepatitis B therapeutic space.
Related Reports
Chronic Hepatitis B Epidemiology
Chronic Hepatitis B Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and the CHB epidemiology trends.
Chronic Hepatitis B Pipeline
Chronic Hepatitis B Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key CHB companies, including Vedanta Biosciences, Gilead Sciences, Dong-A ST Co, Assembly Biosciences, Arbutus Biopharma, Vir Biotechnology, Antios Therapeutics, Ascletis Pharmaceuticals, Shanghai HEP Pharmaceutical, Romark Laboratories, Qilu Pharmaceutical, Golden Biotechnology, Sunshine Lake Pharma, Ascentage Pharma, GlaxoSmithKline, Janssen Sciences, Henlix, Enyo Pharma, Tasly Tianjin Biopharmaceutical, Brii Biosciences, Vaxine Pty Ltd, Vaccitech Limited, Zhejiang Palo Alto Pharmaceuticals, Suzhou Ribo Life Science, PharmaEssentia, Nucorion Pharmaceuticals, Jiangsu HengRui Medicine, Enanta Pharmaceuticals, Chong Kun Dang Pharmaceutical, Guangzhou Lupeng Pharmaceutical, VenatoRx Pharmaceuticals, Zhimeng Biopharm, among others.
Hepatitis A Market
Hepatitis A Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis A companies, including Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, among others.
Hepatitis C Market
Hepatitis C Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hepatitis C companies, including AbbVie, Gilead Sciences, Atea Pharmaceuticals, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/chronic-hepatitis-b-marketthe-us-to-have-the-lions-share-among-the-7mm-predicts-delveinsight-302483263.html
SOURCE DelveInsight Business Research, LLP
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
21 minutes ago
- Medscape
Heat, Poor Air Quality Ups Heart Attack Risk
Simultaneous exposure to ozone pollution and high temperatures significantly increases the risk for acute myocardial infarction (MI) among adults in the US, according to a recent study published in Circulation . The findings highlight the dangers of joint environmental stressors even at moderate levels and the importance of timely patient counseling. Using nationwide private insurance claims data from 2016 to 2020, researchers from Yale School of Public Health, New Haven, Connecticut, and collaborators identified 270,123 cases of acute MI in people aged 18-64 years. They found joint exposure to ground-level ozone (60 ppb) and high temperatures — roughly 90-95 °F — increased the risk for an MI by 33% compared to cooler, low-ozone days. Even under moderate conditions, such as an ozone count of 50 ppb and typical temperatures around 70 °F, the risk increased by 15%. 'The lag 0f effect means clinicians need to pay close attention to high-pollution and hot days in real time,' said Lingzhi Chu, PhD, a postdoctoral associate in the Department of Environmental Health Sciences at the Yale School of Public Health and colead author of the study 'Clinicians should emphasize to younger patients that moderate levels still pose risks' to cardiovascular health. Mary Johnson, PhD, a principal research scientist of environmental health at the Harvard T.H. Chan School of Public Health in Boston, said the findings bring much-needed attention to a younger demographic. 'This study is important because it focuses on a younger age group that is often overlooked in cardiovascular research,' said Johnson, who was not involved in the study. 'Typically, you don't think about heart attacks happening in people in the young adult category.' Johnson also noted the value of examining heat and ozone together. 'We've seen studies showing impacts from temperature and from ozone individually,' she said, 'but looking at them together, and especially looking at differences between men and women, is important.' Different Risks by Sex According to the study, women showed increased vulnerability on days with both high ozone and temperatures around 90-95 degrees, while men experienced heightened risk even when only one factor was elevated. The difference in exposure-response patterns by sex was statistically significant ( P = .016). Chu said clinicians should tailor counseling based on patient demographics. 'The sex difference that males are vulnerable to mild exposures is critical,' Chu said. 'Young men need targeted proactive counselling.' While the researchers did not assess comorbidities like hypertension or diabetes, Chu acknowledged these conditions could affect risk. 'The potential pathophysiology suggests hypertension, diabetes, or obesity may compound risks, but further research is warranted,' Chu said. Johnson said these findings should challenge assumptions in primary care because these clinicians often are the first to encounter patients of the age group studied. 'Just because you're young and healthy does not necessarily rule out the risk of a cardiac event,' she said. 'Especially if there's a combination of poor air quality and elevated temperature.' Communicating Practical Prevention Acute MI is a leading cause of morbidity and mortality globally, with approximately 800,000 cases annually in the US. Adults younger than 55 years, and particularly women, account for a growing share of acute MIs. Chu recommended several practical prevention strategies clinicians can share with patients: Adjusting the timing of outdoor activities, staying hydrated, and using cooling methods such as fans or air conditioning. She also acknowledged the challenge clinicians face in educating patients without overwhelming them. 'Clinicians may consider framing mitigation as simple behavior changes rather than drastic life changes to prevent patient overwhelm,' she said. 'Some of these simple changes — like checking air quality apps, closing windows on high-ozone days, or staying hydrated — support overall health, not just cardiovascular health.' Johnson agreed. 'While we can't individually control wildfires or ozone formation, everyone can be aware of ozone levels and temperature before going outside or doing anything physically strenuous,' she said. Health Equity Concern The study relied on data from individuals with private insurance, a limitation both Chu and Johnson acknowledged. 'That population has access to care,' Johnson said. 'But what about the uninsured or underinsured? They may be more at risk because they often live in areas with worse air quality and lack resources to adapt, like access to cooling systems or healthcare.' She added that events like sudden cardiac death may be underreported in uninsured populations. 'They don't go to the emergency room. They die before they get there,' Johnson said. 'So the real risk may actually be higher than what this study captured.' Johnson said the findings also highlight a critical shift in how clinicians should view environmental risk. 'It's accurate to say we can no longer think about air pollution and environmental risks as being linked only to chronic conditions,' said Johnson. 'There are acute consequences, too, and this study illustrates that clearly.' A study published last month in the journal Epidemiology found prolonged exposure to the particulate matter in wildfire smoke was associated with small increases in the risk for several cardiovascular diseases, especially hypertension. As climate change drives more frequent heat waves and worsens air quality, both Chu and Johnson said clinicians are on the front lines of patient education and prevention. 'Clinicians are key players in translating environmental health research into actionable prevention,' Chu said. 'This study reinforces the need to think beyond traditional risk factors.' Chu and Johnson reported no relevant financial conflicts of interest.
Entrepreneur
32 minutes ago
- Entrepreneur
Quadria Group Launches USD 300 Mn HealthQuad Fund III to Boost Healthcare Innovation
The fund includes a target corpus of USD 200 million and a USD 100 million greenshoe option, aiming to further expand its footprint in the healthcare innovation space across India and Asia. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Quadria Group, a leading healthcare-focused private equity platform, has announced the launch of HealthQuad Fund III, with a proposed fundraise of up to USD 300 million. The fund includes a target corpus of USD 200 million and a USD 100 million greenshoe option, aiming to further expand its footprint in the healthcare innovation space across India and Asia. HealthQuad Fund III follows the success of its predecessor funds, which collectively backed over 18 disruptive, tech-enabled healthcare ventures. These include names like Medikabazaar, THB, Wysa, and Redcliffe Labs, many of which have emerged as category leaders. "With Fund III, we aim to thoughtfully combine Quadria's healthcare expertise, global capital network, and institutional partnerships to build a more integrated healthcare investment platform for India," said Sunil Thakur, Co-founder and Investment Committee Member at HealthQuad. "The encouraging outcomes from Funds I and II give us the confidence to further our mission of creating both financial and social value." HealthQuad was incubated in 2016 as a distinct initiative by Quadria Group to support early-growth healthcare startups with a strong technology focus. Now, with full ownership of Fund III and its separation from former partner KOIS, Quadria is poised to build India's most influential healthcare investment franchise. "India presents one of the world's most compelling healthcare investment opportunities—driven by growing demand, digital acceleration, and underserved segments across primary, diagnostic, and chronic care," said Dr Amit Varma, Co-founder and Investment Committee Member, HealthQuad. "With expanded leadership, we are better positioned than ever to deliver cross-regional value across South Asia, Southeast Asia, and the GCC." Quadria has retained most of its core investment team and plans to strengthen it further with seasoned investing, operating, and clinical professionals. The firm recently closed Quadria Capital Fund III at USD 1.07 billion, highlighting robust investor confidence. "HealthQuad is not just a fund—it's Quadria's conviction in motion," said Abrar Mir, Co-founder and Investment Committee Member. "We've built a unique platform supporting diverse healthcare models, accelerating their growth with our powerful ecosystem." Founded in 2012, Quadria Capital now manages over USD 4 billion in assets across 27 investments in India, Vietnam, Indonesia, Malaysia, and Singapore, with a mission to improve healthcare access, quality, and affordability at scale.
Medscape
an hour ago
- Medscape
Next-Generation Obesity Treatments Take Center Stage at ADA
The upcoming American Diabetes Association (ADA) 85th Scientific Sessions will focus on new and evolving weight-loss treatments for people with and without diabetes, along with new biological and technological approaches for managing type 1 diabetes (T1D). Late-breaking symposia will include data from trials of a once-monthly injectable for obesity treatment, a nonpeptide oral GLP-1 receptor agonist (RA), and a medication combining a GLP-1 RA with another drug designed to augment fat loss while preserving lean mass. Other new findings at the meeting include the use of a GLP-1 RA in T1D and the latest data on stem cell-derived islet cell transplantation in T1D. And always, there's much more. The meeting will take place from June 20 to 24, 2025, in Chicago. 'This year again, it will be heavily focused on obesity but more on the next generation of obesity drugs. We're progressing to therapy that may be more amenable to the patient, with less frequent dosing and greater convenience,' Marlon Pragnell, PhD, ADA's vice president of research and science, told Medscape Medical News . A major theme of the meeting, said Conference Planning Committee Chair Mark A. Atkinson, PhD, director of the University of Florida Diabetes Institute, Gainesville, Florida, will be 'after decades of making moderate impacts on both type 1 and type 2 diabetes, we are now in a position where we're moving from baby steps to big leaps, be it through technology, as well as new drugs for type 2 diabetes (T2D) and obesity. There's a very positive evolution here, but now that we have all these new tools, how do we most effectively use them?' And of course, the 'elephant in the room,' Atkinson noted, is the cost of the new approaches and access, another topic that will be addressed in several sessions. 'Cost is also a huge factor. There will be discussions about cost and cost effectiveness.' Late-breaking symposia topics include the following: Once-monthly maridebart cafraglutide (MariTide, Amgen) for the treatment of obesity in people with or without T2D — a 52-week phase 2 study : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. First report of a phase 3 radomized controlled trial of orforglipron, a small nonpeptide GLP-1 RA, as monotherapy in drug-naïve T2D with inadequate glycemic control — the ACHIEVE-1 trial: These will be the full data for Eli Lilly's investigational product, following the release of top-line results in April 2025. The potential advantages here are not just that it would be an oral GLP-1 RA but because it's a nonpeptide small molecule it could be taken regardless of food or liquid intake, it wouldn't require refrigeration, and could potentially be manufactured more cheaply than injected GLP-1 RAs. 'This is actually very exciting,' Pragnell commented. Can we improve the quality of weight loss by augmenting fat mass loss while preserving lean mass? The BELIEVE study of bimagrumab plus semaglutide: The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. Efficacy and safety of CagriSema 2.4 mg/2.4 mg in adults with overweight/obesity — the REDEFINE 1 and REDEFINE 2 clinical trials: Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. ADJUnct semaglutide treatment in T1D (ADJUST-T1D) trial outcomes: With obesity increasingly recognized as an issue in T1D, the ADJUnct study examined the impact of adding semaglutide to automated insulin delivery. This symposium will include new trial outcomes. Other late-breaking symposia will cover results of the CATALYST trial of treatment of hypercortisolism in difficult to control T2D, new data from the STRIDE trial of semaglutide in peripheral artery disease, and the full data for the SOUL trial of oral semaglutide (Rybelsus) on cardiovascular and other outcomes in people with T2D at high cardiovascular risk. And there's much more, including results from a trial called PATHWEIGH, focusing on weight management in primary care, updates on inhaled insulin, new data on Vertex's stem cell-derived transplanted islets in T1D, and the use of artificial intelligence in diabetes management. According to Atkinson, 'This year's scientific sessions will showcase cutting-edge advancements in diabetes research through a robust, data-focused program. Whether attending in person or watching on-demand, participants will have the chance to connect with top experts, take part in engaging discussions, and gain critical insights that will help shape the future of diabetes care.' Pregnall and Atkinson had no disclosures.
